Cargando…

Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma

In tumor microenvironment, the programmed death 1 (PD-1) immune checkpoint has a crucial role of mechanism of T cell exhaustion leading to tumor evasion. Ligands of PD-1, programmed death ligand 1/2 (PD-L1/L2) are over-expressed in tumor cells and participate in prolonged tumor progression and survi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Moo-Kon, Park, Byeong-Bae, Uhm, Jieun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470519/ https://www.ncbi.nlm.nih.gov/pubmed/30884772 http://dx.doi.org/10.3390/ijms20061326

Ejemplares similares

The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
por: Garcia-Lacarte, Marcos, et al.
Publicado: (2021)

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
por: Kok, Victor C.
Publicado: (2020)

Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
por: Watterson, Alex, et al.
Publicado: (2023)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
por: Xie, Wei, et al.
Publicado: (2022)

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma
por: Fang, Xia, et al.
Publicado: (2017)

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism
por: Raftery, Martin J., et al.
Publicado: (2018)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
por: Prodeus, Aaron, et al.
Publicado: (2015)

Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia
por: Song, Moo-Kon, et al.
Publicado: (2021)

PD-L1-expressing extranodal diffuse large B-cell lymphoma, NOS with and without PD-L1 3’-UTR structural variations
por: Takahara, Taishi, et al.
Publicado: (2022)

A miR-129-5P/ARID3A Negative Feedback Loop Modulates Diffuse Large B Cell Lymphoma Progression and Immune Evasion Through Regulating the PD-1/PD-L1 Checkpoint
por: Zheng, Weili, et al.
Publicado: (2021)

IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
por: Wu, Xuemei, et al.
Publicado: (2023)

Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2021)

Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope
por: Aresu, Luca, et al.
Publicado: (2021)

Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma
por: Saber, Manal Mohamed
Publicado: (2022)

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
por: Ricklefs, Franz L., et al.
Publicado: (2018)

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018)

LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint
por: Zhao, Lina, et al.
Publicado: (2019)

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
por: He, Xiujing, et al.
Publicado: (2022)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target
por: Zhou, Junzhi, et al.
Publicado: (2023)

Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis
por: Song, Moo-Kon, et al.
Publicado: (2018)

RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion
por: Zhang, Yanyan, et al.
Publicado: (2022)

Upregulation of PD‐L1 by SARS‐CoV‐2 promotes immune evasion
por: Huang, Hsiang‐Chi, et al.
Publicado: (2023)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma
por: Rong, Qi-xiang, et al.
Publicado: (2021)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
por: Gu, Qianhui, et al.
Publicado: (2021)

Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma
por: Yan, Shufang, et al.
Publicado: (2022)

Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma
por: Kwon, Hyun Jung, et al.
Publicado: (2018)

Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1
por: Sun, Jing-Ran, et al.
Publicado: (2019)

Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma
por: Lee, Ki Rim, et al.
Publicado: (2022)

Exosomal PD‑L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B‑cell lymphoma
por: Zeng, Hui, et al.
Publicado: (2023)

β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion
por: Du, Linyong, et al.
Publicado: (2020)

Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1
por: Timaner, Michael, et al.
Publicado: (2019)

Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer
por: Cen, Bo, et al.
Publicado: (2021)

RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
por: Zhang, Yangyang, et al.
Publicado: (2023)

PD-L1 Status in Refractory Lymphomas
por: Vranic, Semir, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s63hapcatghut5qpjbp4volf0a